Kanuma

Active Ingredient(s): Sebelipase Alfa
FDA Approved: * December 8, 2015
Pharm Company: * ALEXION PHARM

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Kanuma Overview

Sebelipase alfa, sold under the brand name Kanuma, is a recombinant form of the enzyme lysosomal acid lipase (LAL) that is used as a medication for the treatment of lysosomal acid lipase deficiency (LAL-D).[2][3] It is administered via intraveneous infusion.[4] It was approved for medical use in the European Union and in the United States in 2015.[5][2][4][3] Contents 1 Medical ...

Read more Kanuma Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Sebelipase_alfa

Recent Kanuma Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Sebelipase Alfa
  • Injection: 20mg/10ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Kanuma: (1 result)

Sorted by National Drug Code
  • 25682-007 Kanuma 2 mg/ml Intravenous Injection, Solution, Concentrate by Alexion Pharmaceuticals, Inc.

Other drugs which contain Sebelipase Alfa or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 15 August 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA